Stockreport

Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update

Belite Bio, Inc - American Depositary Shares  (BLTE) 
PDF Dosed first patient in Phase 2/3 DRAGON II trial of Tinlarebant for the treatment of Stargardt disease (STGD1)Pivotal global Phase 3 PHOENIX trial of Tinlarebant in geog [Read more]